Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Conditions
Brief summary
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Detailed description
The proposed study is a single arm, open-label Phase I/II trial of Seleno-L Methionine (SLM) in sequential combination with the standard dose and schedule of Axitinib and Pembrolizumab in previously untreated patients with advanced ccRCC. The hypothesis is that adding SLM to the Pembrolizumab and Axitinib combination will improve efficacy without added toxicity. This is a two-part study: * Escalation Part 1: The study will begin with a dose-escalation study to find the maximum tolerated dose (MTD) of study drug, SLM. * Expansion Part 2: Once the appropriate dose of SLM is determined, the second part of the study will begin.
Interventions
Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
DRUGAxitinib
Axitinib is a small molecule tyrosine kinase inhibitor.
DRUGPembrolizumab
Pembrolizumab is a type of immunotherapy
Sponsors
University of Iowa
Mohammed Milhem
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be eligible to participate in this study, an individual must meet all the following criteria: * Written and voluntary informed consent. * Histologically and radiologically confirmed locally advanced or metastatic ccRCC. Locally advanced is defined as non resectable in the opinion of the treating providers. Participants must be treatment naïve in metastatic setting. Prior immunotherapy treatment in adjuvant setting is allowed. * \> 18 years of age * At least one Response Evaluation Criteria in Solid Tumors (RECIST 1.1)-defined target lesion that has not been irradiated * Eastern Cooperative Oncology Group performance status of 0 (fully active, able to carry on all pre-disease performance without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work). * Renal function (creatinine level within normal institutional limit, or creatinine clearance \>15 mL/min/1.73 m2 for patients with creatinine levels above institutional normal, calculated using the Cockcroft-Gault formula). * Liver function (AST/ALT \<3.0 X institutional upper limit of normal OR \< 5 x institutional upper limit of normal in cases of liver metastases; Total bilirubin ≤ 1.5 times ULN.) * Adequate hematological lab values including * Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L * Platelets ≥ 100 x 109/L * Hemoglobin ≥ 7.0 g/dL * Has adequately controlled BP with or without antihypertensive medications, defined as BP ≤150/90 mm Hg with no change in antihypertensive medications within 1 week before randomization/allocation. * Female subjects of childbearing potential and non-sterilized male subjects who intend to be sexually active during the study must agree to use a highly effective method of contraception from the time of screening, throughout the total duration of the drug treatment, and during the 6 month post-drug washout period. See section 5.6 for full details.
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: * Patients with a prior or concurrent malignancy whose natural history or treatment may have the potential to interfere with the safety or efficacy assessment of the investigational regimen. * Untreated metastases in the central nervous system. * Pregnant or breastfeeding. * Present use or anticipated need for cytochrome P450 (CYP) 3A4-inhibiting, CYP3A4-inducing drugs (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, and St. John's wort, bosentan, efavirenz, etravirine, modafinil, and nafcillin). * Myocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous 6 months. Participants with history of deep vein thrombosis or pulmonary embolism, at provider discretion. * Major surgery within 4 weeks of starting study treatment. * Patients with HIV infection with CD4+ T-cell (CD4+) counts \< 350 cells/uL * Patients with HIV infection and a history of AIDS-defining opportunistic infections No exclusions will be made based on sex, race, or ethnic background.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I - Dose limiting toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | From the initiation of treatment through three years | To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients |
| Phase II - Objective Response Rate (ORR) | From the initiation of treatment through three years | ORR will be defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From the initiation of treatment through three years | PFS will be defined as the time from treatment initiation to the date of first documentation of disease progression or death due to any cause |
| Overall survival (OS) | From the initiation of treatment through three years | OS will be defined as the time from treatment initiation to the date of death due to any cause |
Countries
United States
Outcome results
None listed